{"id":"NCT02361216","sponsor":"LEO Pharma","briefTitle":"Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest","officialTitle":"Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2016-03","completion":"2017-03","firstPosted":"2015-02-11","resultsPosted":"2018-10-03","lastUpdate":"2025-03-10"},"enrollment":729,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"Ingenol Mebutate","otherNames":[]},{"type":"OTHER","name":"Vehicle","otherNames":[]}],"arms":[{"label":"Ingenol mebutate gel","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.","primaryOutcome":{"measure":"Percentage of Participants With Complete Resolution of Actinic Keratosis (AK)","timeFrame":"8 weeks","effectByArm":[{"arm":"Ingenol Mebutate Gel","deltaMin":21.4,"sd":null},{"arm":"Vehicle","deltaMin":3.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":549},"commonTop":["Application Site Pain","Application Site Pruritus","Application Site Discomfort","headache","application site parasthesia"]}}